DNTH Dianthus Therapeutics, Inc.
Price Chart
Executive Summary
Dianthus Therapeutics reported full-year 2025 financial results and announced a positive GO decision in the Phase 3 CAPTIVATE trial of claseprubart for CIDP, based on achieving 20 confirmed responders in the interim analysis. The company has $514.4 million in cash, providing a runway into 2028, despite a widening net loss driven by increased R&D spending. Top-line data from multiple late-stage trials are expected in 2026–2028.
Key Financial Metrics
Actionable Insight
The early GO decision in CAPTIVATE de-risks the CIDP program and supports upcoming Phase 3 initiation in gMG. With multiple near-term catalysts (MMN data in 2H'26, gMG trial start, DNTH212 data), the stock may re-rate on continued clinical execution. Monitor Part B guidance for CAPTIVATE by YE'26.
Key Facts
- Achieved early GO decision in Phase 3 CAPTIVATE trial for CIDP based on 20 confirmed responders with less than 40 participants completing Part A.
- Phase 3 trial in gMG expected to initiate mid-2026 with top-line results in 2H'28.
- Phase 2 MoMeNtum trial in MMN on track for top-line results in 2H'26.
- Phase 1 data for DNTH212 in healthy volunteers expected in 2H'26.
- Cash position of $514.4 million as of December 31, 2025, sufficient to fund operations into 2028.
- R&D expenses increased to $145.6 million in 2025 from $83.1 million in 2024, primarily due to clinical development and headcount growth.
- Net loss for 2025 was $162.3 million ($4.20 per share), up from $85.0 million ($2.55 per share) in 2024.
Financial Impact
Increased R&D spend by $62.5 million YoY; net loss nearly doubled to $162.3 million. Cash runway extended to 2028 despite higher burn.
Risk Factors
- Interim data from open-label Part A of CAPTIVATE is not randomized or controlled; final results may differ.
- No revenue from product sales; reliant on capital markets for future funding beyond 2028.
- Increased stock-based compensation contributing to higher G&A and R&D expenses.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3251709 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 5, 2026
5w ago
|
8-K
| $90.42 $84.97 | ▼ −6.03% | ▼ −8.81% | $81.22 (−10.17%) |
|
Mar 12, 2026
12w ago
|
Press Release
| $77.86 $90.00 | ▲ +15.59% | ▲ +12.00% | $81.22 (+4.32%) |
|
Mar 12, 2026
12w ago
|
8-K
| $80.32 $89.77 | ▲ +11.77% | ▲ +9.79% | $81.22 (+1.12%) |
|
Mar 12, 2026
12w ago
|
Insider Cluster
| $80.32 $89.77 | ▼ −11.77% | ▼ −9.79% | $81.22 (−1.12%) |
|
Mar 12, 2026
12w ago
|
Insider Cluster
| $80.32 $89.77 | ▼ −11.77% | ▼ −9.79% | $81.22 (−1.12%) |
|
Mar 11, 2026
13w ago
|
Press Release
| $85.84 $91.66 | ▲ +6.78% | ▲ +6.26% | $81.22 (−5.38%) |
|
Mar 9, 2026
13w ago
|
Press Release
| $79.23 $86.20 | ▲ +8.80% | ▲ +11.60% | $81.22 (+2.51%) |
|
Mar 8, 2026
13w ago
|
Press Release
| $79.23 $86.20 | ▲ +8.80% | ▲ +11.60% | $81.22 (+2.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access